ClinicalTrials.gg
RecruitingNCT07583823Updated Nov 12, 2026

Elevated Rate Pacing of Cardiac Amyloidosis

An interventional study of Pacemaker Rate in Cardiac Amyloidosis and Pacemaker, sponsored by University of Minnesota. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by University of Minnesota · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Oct 2025, registered May 2026).
  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Nov 12, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Amyloid Neuropathies, Familial with a site in United States — 23 open to participants now, 26 under way, 4 of them phase 3. Amyloid Neuropathies, Familial · United States.

Planned enrollment
33rd of 38
10 · median 53
Started
2025
with 6 others
No phase
6 of 58
4 open now
Primary completion
2026-12
later than 3 of 25 live
Registered
55th of 58
by date

Among the 58 studies in Amyloid Neuropathies, Familial with a site in United States, this one is the 33rd largest by planned enrollment of the 38 interventional ones that give a count, is one of 7 that started in 2025, is one of 6 with no phase, reaches primary completion later than 3 of the 25 other live ones, and was the 55th registered.

Amyloid Neuropathies, Familial

188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.

Browse Amyloid Neuropathies, Familial studies →

Open to participants now

23 of the 58 studies in Amyloid Neuropathies, Familial with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Amyloid Neuropathies, Familial with a site in United States, or all of them as a file.
02

Study summary

This study aims to better quantify the improvements in heart failure symptoms and exercise tolerance before and after the heart rate elevation in a cohort of 10 cardiac amyloidosis patients with preexisting pacemakers.

03

Conditions studied

  • Cardiac Amyloidosis
  • Pacemaker
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18 and older
  • Diagnosis of cardiac amyloidosis as indicated by the criteria set forth in guidelines such as in Kittleson et al: "2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee
  • Implanted Cardiac Pacemaker (+/- Defibrillator)
  • Pacemaker mode of AAI or DDD if in sinus rhythm, VVI acceptable if permanent atrial fibrillation
  • Non-dilated left ventricle by echocardiography
  • Ability to provide written consent
  • English Speaking

Exclusion criteria

Exclusion Criteria:

  • Paced QRS duration of >150 ms (indicator for pacing mediated dyssynchrony)
  • Dilated left ventricle
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Elevated Pacemaker Rate

    CA clinic patients with pacemakers will receive a personalized pacing protocol individual to their height and left ventricular ejection fraction.

    Other: Pacemaker Rate

Interventions

  • OtherPacemaker Rate

    CA clinic patients with pacemakers will receive a personalized pacing protocol individual to their height and left ventricular ejection fraction.

06

What researchers measure

Primary outcomes

  1. Kansas City Cardiomyopathy Questionnaire Score

    75-100 representing good to excellent health, and 0-24 representing very poor to poor health

    Time frame: Month 4

  2. Composite of any cardiovascular event

    admission or urgent visit for heart failure and atrial fibrillation, myocardial infarction or stroke

    Time frame: Month 4

07

Study locations

1 of 1 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.

Of 30 interventional studies with no phase under Amyloid Neuropathies, Familial, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 67. This study's planned 13 months is below that.

Primary completion moved twice since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, last on Nov 12, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, last on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2026
First posted
May 13, 2026
StartActual
Oct 10, 2025
Primary completionEst.
Dec 4, 2026was Oct 2026
CompletionEst.
Dec 4, 2026was Oct 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 10, 2026→Dec 4, 2026
moved 2 times, Oct 13, 2026 – Nov 12, 2026
Study completion
Oct 10, 2026→Dec 4, 2026
moved 2 times, Oct 13, 2026 – Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    Primary completion Nov 10, 2026→Dec 4, 2026
    Study completion Nov 10, 2026→Dec 4, 2026
    + 1 other change: verification date
  2. Oct 13, 2026
    Primary completion Oct 10, 2026→Nov 10, 2026
    Study completion Oct 10, 2026→Nov 10, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07583823
Responsible party
Sponsor
First posted
May 13, 2026
Start date
Oct 10, 2025
Primary completion
Dec 4, 2026 (estimated)
Completion
Dec 4, 2026 (estimated)
Last update
Nov 12, 2026

Study contacts

Meghan Muscala
Contact
payne324@umn.edu
612-626-5863
Valmiki Maharaj
principal investigator · University of Minnesota

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion